Neuronetics (STIM) Q1 2026: Clinic Revenue Jumps 15% as Buy-and-Bill Drives Growth

2026-05-05 | By EarningsIQ Research

Clinic-led growth and operational discipline defined Neuronetics’ first quarter under new leadership. While NeuroStar system sales improved, treatment revenue softened and gross margin compressed as clinics took a larger role in the revenue mix. With pilots underway to broaden commercial models and a sharpened focus on workflow and cash, Neuronetics is positioning for a more resilient, profitable trajectory—though investor debate over business separation and capital allocation remains unresolved.

Summary

• Clinic Revenue Momentum: Greenbrook clinics led growth, offsetting softness in NeuroStar treatment sales.
• Go-to-Market Expansion: Pilots aim to diversify NeuroStar’s commercial approach and unlock underpenetrated segments.
• Profitability Focus: Cost actions and cash discipline are central as management targets flat to positive cash flow in 2H26.

Business Overview

Neuronetics develops and commercializes non-invasive neuromodulation therapies for psychiatric disorders, primarily through its NeuroStar Transcranial Magnetic Stimulation (TMS) system, a device-based treatment for depression. The company operates two primary segments: NeuroStar (system sales and per-treatment revenue from TMS devices) and Greenbrook clinics (company-operated clinics providing TMS and Spravato, a ketamine-based therapy, directly to patients). Revenue is generated from device sales, ongoing treatment sessions, and direct clinic operations, with an increasing share from the clinic footprint.

Performance Analysis

Neuronetics delivered 8% total revenue growth in Q1 2026, driven by a 15% surge in U.S. clinic revenue, while NeuroStar system and treatment sales saw mixed results. Notably, NeuroStar system shipments rose 10% year over year, reflecting momentum in capital equipment adoption, yet treatment session revenue fell 5% as customer inventory drawdowns and weather disruptions weighed on volumes. Clinic growth was propelled by Spravato buy-and-bill, a model where clinics purchase and administer the drug, expanding both volume and pricing leverage.

Gross margin declined to 46.9% from 49.2% a year ago, reflecting the shift toward lower-margin clinic revenue and increased Spravato buy-and-bill mix. Operating expenses fell 6% due to SG&A efficiency efforts, and net loss improved, with adjusted EBITDA narrowing by $2 million. Operating cash burn improved substantially to $9.4 million, down from $17 million in Q1 2025, aided by cost actions and a debt amendment that reduced interest expense.

• Clinic Revenue Outpaces Core Device Growth: Greenbrook clinics now comprise the majority of revenue, with Spravato driving both volume and margin impact.
• NeuroStar System Shipments Rise, But Utilization Lags: System sales up 10%, yet per-treatment revenue slipped as clinics managed inventory and weather dampened Q1 throughput.
• Cost Structure Realignment: SG&A savings and a $2.5–$3 million annualized cost action support the path to cash flow breakeven.

Cash discipline and margin management are central themes, as Neuronetics seeks to balance growth with profitability in a capital-intensive, evolving therapeutic landscape.

Executive Commentary

Strategic Positioning

1. Clinic Model Scaling and Operational Leverage

Greenbrook clinics are now the primary growth engine, with Spravato adoption and buy-and-bill expansion driving both patient access and pricing power. Management is focused on workflow optimization and revenue cycle management to improve collections and clinic-level profitability, leveraging lessons from prior vertically integrated medtech roles.

2. NeuroStar Commercial Model Diversification

Neuronetics is piloting new go-to-market models for NeuroStar, aiming to address untapped customer segments with differentiated support and economic options. By tailoring support levels and pricing, the company seeks to expand its addressable market and better align with varied customer needs, potentially catalyzing system sales and utilization growth.

3. Margin and Cash Flow Discipline

Cost reduction and cash management are explicit leadership priorities, with $2.5–$3 million in annualized savings targeted and a goal of achieving flat to positive operating cash flow in the second half of 2026. The recent debt amendment reduces interest burden, providing additional flexibility as the company navigates a capital-intensive transition phase.

4. Strategic Review and Portfolio Optionality

Amid shareholder calls for a business separation, leadership is evaluating all options with an open mind but is not rushing to a decision. The board remains focused on long-term value creation, and management is actively engaging with stakeholders while prioritizing operational execution and strategic clarity.

5. Pipeline and Policy Catalysts

The pending Compass Pathways psilocybin therapy could provide a future growth lever, with Greenbrook’s infrastructure uniquely positioned to deliver such advanced therapies if approved. Recent policy moves may accelerate this timeline, but management expects a measured adoption curve, similar to Spravato’s rollout.

Key Considerations

The first quarter under new CEO Dan Revers demonstrates a pragmatic, operationally focused approach, with clear emphasis on execution, cost discipline, and market responsiveness. Investors should weigh the durability of clinic-led growth against the margin pressure and the pace at which NeuroStar’s commercial pilots can reignite device and treatment momentum.

Key Considerations:

• Clinic Mix Shift: The increasing share of lower-margin clinic revenue pressures gross margin, requiring ongoing operational efficiency gains to protect profitability.
• NeuroStar Model Evolution: Success of pilot programs to broaden commercial offerings will be critical for reigniting system and utilization growth.
• Cash and Capital Allocation: With $19 million in cash and improved burn rates, balance sheet flexibility is adequate for 2026, but longer-term funding needs depend on execution and margin recovery.
• Stakeholder Alignment: Ongoing shareholder activism and board openness to business separation create both risk and optionality for future value realization.
• Therapy Pipeline Readiness: Greenbrook’s infrastructure gives it a first-mover advantage if psilocybin or similar therapies gain approval, but ramp will be gradual.

Risks

Margin compression from clinic mix, execution risk in commercial model pilots, and reliance on Spravato and TMS reimbursement policy changes all present material uncertainties. Capital needs are manageable in 2026 but could resurface if growth or margin targets slip. Shareholder pressure for strategic alternatives may distract from operational focus if not managed carefully.

Forward Outlook

For Q2 2026, Neuronetics guided to:

• Mid-single-digit revenue growth sequentially
• Improving operating cash flow, with positive or flat cash flow targeted in 2H26

For full-year 2026, management maintained guidance:

• Total revenue of $160–$166 million
• Gross margin of 47–49%
• Operating expenses of $100–$105 million
• Operating cash flow of negative $13–$17 million, with improvements expected each quarter

Management emphasized that pilots to expand NeuroStar’s commercial reach and ongoing cost discipline will drive sequential improvement. The company expects benefits from workflow and revenue cycle initiatives to build through the year, and sees potential upside if policy or pipeline therapies accelerate.

• Clinic revenue is expected to remain a key growth driver
• Cash flow improvement is central to capital allocation strategy

Takeaways

Neuronetics is navigating a strategic inflection, balancing clinic-led growth with operational discipline and commercial model innovation. Investors should monitor the pace of NeuroStar pilot adoption, margin recovery, and capital allocation decisions as the company responds to both market opportunity and shareholder activism.

• Clinic Growth Offsets NeuroStar Treatment Softness: Spravato buy-and-bill and clinic operations are driving top-line gains, but at the expense of gross margin, requiring continued operational focus.
• Commercial Model Pilots Are a Key Catalyst: The success of new go-to-market approaches for NeuroStar will determine if the core device business can reignite growth and margin leverage.
• Capital Discipline and Strategic Optionality Remain in Focus: With improved cash flow and a patient leadership approach, the company is positioned to evaluate portfolio moves while prioritizing execution.

Conclusion

Neuronetics’ Q1 2026 reflects a business in disciplined transition, with clinics leading growth and new leadership prioritizing operational rigor, cash discipline, and commercial innovation. The path forward hinges on execution of commercial pilots and the ability to manage margin pressure as the business model evolves.

Industry Read-Through

Neuronetics’ results underscore a broader trend in medtech: vertical integration and direct clinic models can drive growth but may compress margins if not paired with operational efficiency. The shift to buy-and-bill and expanded therapy offerings, such as Spravato and potential psilocybin therapies, signals a growing role for clinic infrastructure and reimbursement agility in behavioral health. For device makers and specialty clinics, success will increasingly depend on the ability to tailor commercial models and capitalize on policy tailwinds. The evolving mix of device, drug, and service revenue offers both opportunity and complexity for the sector, with margin management and capital allocation as persistent themes.

STIM Health Care Medical Devices Clinic Operations Spravato TMS Cash Flow Go-to-Market